AU2001237875B2 - New self emulsifying drug delivery system - Google Patents
New self emulsifying drug delivery system Download PDFInfo
- Publication number
- AU2001237875B2 AU2001237875B2 AU2001237875A AU2001237875A AU2001237875B2 AU 2001237875 B2 AU2001237875 B2 AU 2001237875B2 AU 2001237875 A AU2001237875 A AU 2001237875A AU 2001237875 A AU2001237875 A AU 2001237875A AU 2001237875 B2 AU2001237875 B2 AU 2001237875B2
- Authority
- AU
- Australia
- Prior art keywords
- oil
- pharmaceutical composition
- surfactant
- pharmaceutical
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000012377 drug delivery Methods 0.000 title description 4
- 230000001804 emulsifying effect Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 claims description 81
- 239000002775 capsule Substances 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 46
- 239000000839 emulsion Substances 0.000 claims description 41
- 239000004094 surface-active agent Substances 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 23
- 239000003921 oil Substances 0.000 claims description 22
- 235000019198 oils Nutrition 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 229920001992 poloxamer 407 Polymers 0.000 claims description 18
- 239000012141 concentrate Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 229920001983 poloxamer Polymers 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 238000011065 in-situ storage Methods 0.000 claims description 10
- 239000001828 Gelatine Substances 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 235000019197 fats Nutrition 0.000 claims description 8
- 239000007764 o/w emulsion Substances 0.000 claims description 8
- 229940044476 poloxamer 407 Drugs 0.000 claims description 8
- 150000001298 alcohols Chemical class 0.000 claims description 7
- 229920001987 poloxamine Polymers 0.000 claims description 7
- -1 polyoxyethylene Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001400 block copolymer Polymers 0.000 claims description 6
- 239000003240 coconut oil Substances 0.000 claims description 6
- 235000019864 coconut oil Nutrition 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 150000005690 diesters Chemical class 0.000 claims description 4
- 229920002516 Poloxamer 331 Polymers 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 230000035622 drinking Effects 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229920002511 Poloxamer 237 Polymers 0.000 claims description 2
- 229920002517 Poloxamer 338 Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000019485 Safflower oil Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 150000005691 triesters Chemical class 0.000 claims description 2
- 101150039033 Eci2 gene Proteins 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 36
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 20
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 19
- 239000012669 liquid formulation Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 238000011179 visual inspection Methods 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 13
- 238000011049 filling Methods 0.000 description 13
- 239000007903 gelatin capsule Substances 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000003760 magnetic stirring Methods 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000000693 micelle Substances 0.000 description 6
- 239000000155 melt Substances 0.000 description 5
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 4
- 239000008389 polyethoxylated castor oil Substances 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000004064 cosurfactant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 229920000151 polyglycol Polymers 0.000 description 3
- 239000010695 polyglycol Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 229920002023 Pluronic® F 87 Polymers 0.000 description 1
- 229920002035 Pluronic® L 10 Polymers 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- 229920002366 Tetronic® 1307 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000002267 linear dichroism spectroscopy Methods 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000774A SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | New formulation |
| SE0000774-0 | 2000-03-08 | ||
| PCT/SE2001/000466 WO2001066087A1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001237875A1 AU2001237875A1 (en) | 2001-11-29 |
| AU2001237875B2 true AU2001237875B2 (en) | 2005-05-12 |
Family
ID=20278740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001237875A Ceased AU2001237875B2 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
| AU3787501A Pending AU3787501A (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3787501A Pending AU3787501A (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7736666B2 (enExample) |
| EP (1) | EP1267831B1 (enExample) |
| JP (1) | JP4656479B2 (enExample) |
| KR (1) | KR100771318B1 (enExample) |
| CN (1) | CN1283229C (enExample) |
| AR (1) | AR027554A1 (enExample) |
| AT (1) | ATE311173T1 (enExample) |
| AU (2) | AU2001237875B2 (enExample) |
| BR (1) | BR0109012B1 (enExample) |
| CA (1) | CA2401857A1 (enExample) |
| CZ (1) | CZ303524B6 (enExample) |
| DE (1) | DE60115402T2 (enExample) |
| DK (1) | DK1267831T3 (enExample) |
| EE (1) | EE200200483A (enExample) |
| ES (1) | ES2253354T3 (enExample) |
| HU (1) | HU229103B1 (enExample) |
| IL (1) | IL151380A0 (enExample) |
| IS (1) | IS6538A (enExample) |
| MX (1) | MXPA02008658A (enExample) |
| MY (1) | MY137749A (enExample) |
| NO (1) | NO331921B1 (enExample) |
| RU (1) | RU2275908C2 (enExample) |
| SE (1) | SE0000774D0 (enExample) |
| SI (1) | SI1267831T1 (enExample) |
| SK (1) | SK285749B6 (enExample) |
| UA (1) | UA76098C2 (enExample) |
| WO (1) | WO2001066087A1 (enExample) |
| ZA (1) | ZA200207109B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| SE0102993D0 (sv) * | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
| AU2003900887A0 (en) * | 2003-02-27 | 2003-03-13 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
| US8802116B2 (en) | 2003-02-27 | 2014-08-12 | Novasel Australia Pty. Ltd. | Poloxamer emulsion preparations |
| DE10353937A1 (de) * | 2003-11-18 | 2005-06-30 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Übertragung einer Referenzflüssigkeit in ein Messgerät, Messgerät mit einer solchen Vorrichtung und Verfahren zur Übertragung einer Referenzflüssigkeit in ein Messgerät |
| GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
| NZ550894A (en) * | 2004-05-06 | 2011-02-25 | Emisphere Tech Inc | Solid dosage form of wetted heparin |
| US8273794B2 (en) | 2004-05-14 | 2012-09-25 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| KR100654617B1 (ko) * | 2004-09-23 | 2006-12-08 | 정해현 | 스틱이 내장된 커피믹스 팩과 커피믹스 박스 |
| HRP20110025T1 (hr) * | 2005-07-26 | 2011-03-31 | Nicox S.A. | FARMACEUTSKA FORMULACIJA NITROOKSIDERIVATA NSAID-a |
| DK2268160T3 (da) | 2008-03-20 | 2013-01-07 | Virun Inc | Emulsioner omfattende et PEG-derivat af tokoferol |
| EP2268274B1 (en) | 2008-03-20 | 2012-05-16 | Virun, Inc. | Vitamin e derivatives and their uses |
| US9717703B2 (en) | 2009-10-16 | 2017-08-01 | Glaxosmithkline Llc | Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed |
| US8741373B2 (en) | 2010-06-21 | 2014-06-03 | Virun, Inc. | Compositions containing non-polar compounds |
| US9968557B1 (en) | 2011-02-09 | 2018-05-15 | Florida A&M University | Method of preparing modified multilayered microstructures with enhanced oral bioavailability |
| KR20240076240A (ko) * | 2022-11-23 | 2024-05-30 | (주) 바이오인프라생명과학 | 더블 에멀젼 구조의 초음파 감응형 약물전달체를 생성하는 방법 |
| WO2025219169A1 (en) | 2024-04-16 | 2025-10-23 | Bayer Consumer Care Ag | Stable soft capsule preparations with liquid fill for moisture sensitive active ingredients |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995008983A1 (fr) * | 1993-09-30 | 1995-04-06 | Gattefosse S.A. | Composition administrable par voie orale apte a former une microemulsion |
| WO1995009831A1 (en) * | 1993-10-06 | 1995-04-13 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
| WO1999056727A2 (en) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| CY1398A (en) | 1981-09-04 | 1987-12-18 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| JPS59227870A (ja) | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | 新規２−グアニジノチアゾリン誘導体ならびにその製造法 |
| US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
| US4522826A (en) | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4552899A (en) | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| US4766117A (en) | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4676984A (en) | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
| US4704278A (en) | 1984-10-17 | 1987-11-03 | American Home Products Corp (Del) | Fluidized magaldrate suspension |
| US5043358A (en) | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
| US4757060A (en) | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
| US5037815A (en) | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
| US4965065A (en) | 1986-04-29 | 1990-10-23 | Bristol-Myers Squibb Company | Gastroprotective process and compositions |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5260333A (en) | 1986-08-08 | 1993-11-09 | Bristol Myers Squibb Company | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
| GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| EP0320550A1 (en) | 1987-12-18 | 1989-06-21 | Bristol-Myers Company | Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent |
| SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| NZ235877A (en) | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
| CA2104684A1 (en) | 1991-03-04 | 1992-09-05 | Mahdi B. Fawzi | Salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
| DE4131678A1 (de) | 1991-04-13 | 1992-10-15 | Beiersdorf Ag | Stabile multiple emulsionen |
| ES2130152T3 (es) | 1991-12-06 | 1999-07-01 | Glaxo Group Ltd | Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto. |
| WO1993012817A1 (en) | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| US5294433A (en) | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| EP0663839A4 (en) | 1992-09-29 | 1998-06-03 | Merck & Co Inc | Ibuprofen-h 2? antagonist combinations. |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| DK66493D0 (da) | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
| SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| US6312704B1 (en) * | 1993-09-30 | 2001-11-06 | Gattefosse, S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US5514663A (en) | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
| WO1995011024A1 (en) | 1993-10-19 | 1995-04-27 | The Procter & Gamble Company | Picosulphate dosage form |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US5643960A (en) | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| AU702662B2 (en) | 1994-05-10 | 1999-02-25 | Nicox S.A. | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic acitivities |
| MX9600857A (es) | 1994-07-08 | 1997-06-28 | Astra Ab | Forma de dosificacion i en tabletas, con unidades multiples. |
| SE9500478D0 (sv) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US5965160A (en) * | 1995-04-24 | 1999-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
| US5955451A (en) | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| CA2271799A1 (en) | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| US6160020A (en) | 1996-12-20 | 2000-12-12 | Mcneill-Ppc, Inc. | Alkali metal and alkaline-earth metal salts of acetaminophen |
| SE510666C2 (sv) | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| NZ502566A (en) * | 1997-07-29 | 2002-03-28 | Upjohn Co | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation containing a pyranone and a basic amine |
| JP2001515854A (ja) | 1997-09-11 | 2001-09-25 | ニュコメデ ダンマルク アクティーゼルスカブ | 非ステロイド性抗炎症薬物質（ＮＳＡＩＤｓ）の改良された開放性多重−単位組成物 |
| JP2001521910A (ja) | 1997-10-31 | 2001-11-13 | モンサント カンパニー | ゲランガム錠剤コーティング |
| CA2320963A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor, Inc. | R-lansoprazole compositions and methods |
| AU2481899A (en) | 1998-01-30 | 1999-08-16 | Sepracor, Inc. | S-lansoprazole compositions and methods |
| EP0984012A3 (en) | 1998-08-31 | 2001-01-10 | Pfizer Products Inc. | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties |
| EP1117386B1 (en) | 1998-09-28 | 2004-12-01 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| US6485747B1 (en) | 1998-10-30 | 2002-11-26 | Monsanto Company | Coated active tablet(s) |
| CN1236813C (zh) * | 1998-12-11 | 2006-01-18 | 药品处理公司 | 水难溶性药物的自乳化组合物 |
| US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| JP4638053B2 (ja) | 1999-03-31 | 2011-02-23 | ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン |
| AU4198899A (en) | 1999-05-20 | 2000-12-12 | Par Pharmaceutical, Inc. | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| US6126816A (en) * | 1999-07-14 | 2000-10-03 | Ruiz, Jr.; Reuben F. | Wastewater treatment device |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| US6787164B2 (en) | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
| SE0000773D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| SE0002476D0 (sv) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20020045184A1 (en) | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
| FR2818905A1 (fr) * | 2000-12-28 | 2002-07-05 | Cll Pharma | Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile |
| AR036354A1 (es) | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | Preparacion solida |
| US7467633B2 (en) * | 2005-03-10 | 2008-12-23 | Huntsman Petrochemical Corporation | Enhanced solubilization using extended chain surfactants |
-
2000
- 2000-03-08 SE SE0000774A patent/SE0000774D0/xx unknown
-
2001
- 2001-02-26 AR ARP010100864A patent/AR027554A1/es not_active Application Discontinuation
- 2001-03-06 BR BRPI0109012-7A patent/BR0109012B1/pt not_active IP Right Cessation
- 2001-03-06 AU AU2001237875A patent/AU2001237875B2/en not_active Ceased
- 2001-03-06 KR KR1020027011733A patent/KR100771318B1/ko not_active Expired - Fee Related
- 2001-03-06 EP EP01910304A patent/EP1267831B1/en not_active Expired - Lifetime
- 2001-03-06 CN CNB018062938A patent/CN1283229C/zh not_active Expired - Fee Related
- 2001-03-06 EE EEP200200483A patent/EE200200483A/xx unknown
- 2001-03-06 IL IL15138001A patent/IL151380A0/xx not_active IP Right Cessation
- 2001-03-06 CA CA002401857A patent/CA2401857A1/en not_active Abandoned
- 2001-03-06 ES ES01910304T patent/ES2253354T3/es not_active Expired - Lifetime
- 2001-03-06 SK SK1258-2002A patent/SK285749B6/sk not_active IP Right Cessation
- 2001-03-06 JP JP2001564740A patent/JP4656479B2/ja not_active Expired - Fee Related
- 2001-03-06 MX MXPA02008658A patent/MXPA02008658A/es active IP Right Grant
- 2001-03-06 HU HU0300539A patent/HU229103B1/hu not_active IP Right Cessation
- 2001-03-06 DK DK01910304T patent/DK1267831T3/da active
- 2001-03-06 SI SI200130487T patent/SI1267831T1/sl unknown
- 2001-03-06 DE DE60115402T patent/DE60115402T2/de not_active Expired - Lifetime
- 2001-03-06 CZ CZ20023006A patent/CZ303524B6/cs not_active IP Right Cessation
- 2001-03-06 US US10/221,079 patent/US7736666B2/en not_active Expired - Fee Related
- 2001-03-06 WO PCT/SE2001/000466 patent/WO2001066087A1/en not_active Ceased
- 2001-03-06 RU RU2002122745/15A patent/RU2275908C2/ru not_active IP Right Cessation
- 2001-03-06 AT AT01910304T patent/ATE311173T1/de active
- 2001-03-06 AU AU3787501A patent/AU3787501A/xx active Pending
- 2001-03-07 MY MYPI20011044A patent/MY137749A/en unknown
- 2001-06-03 UA UA2002086882A patent/UA76098C2/uk unknown
-
2002
- 2002-09-03 NO NO20024194A patent/NO331921B1/no not_active IP Right Cessation
- 2002-09-03 IS IS6538A patent/IS6538A/is unknown
- 2002-09-04 ZA ZA200207109A patent/ZA200207109B/en unknown
-
2010
- 2010-04-28 US US12/768,820 patent/US20100266683A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995008983A1 (fr) * | 1993-09-30 | 1995-04-06 | Gattefosse S.A. | Composition administrable par voie orale apte a former une microemulsion |
| WO1995009831A1 (en) * | 1993-10-06 | 1995-04-13 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
| WO1999056727A2 (en) * | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100266683A1 (en) | New self emulsifying drug delivery system | |
| EP1267832B1 (en) | SELF EMULSIFYING DRUG DELIVERY SYSTEM, wherein the fatty agent is optional | |
| AU2001237875A1 (en) | New self emulsifying drug delivery system | |
| AU2001237876A1 (en) | New self emulsifying drug delivery system | |
| EP1427392B1 (en) | New self emulsifying drug delivery system | |
| HK1050632B (en) | Self emulsifying drug delivery system, wherein the fatty agent is optional | |
| PL203549B1 (pl) | Kompozycja farmaceutyczna w postaci prekoncentratu emulsji, jednostkowa posta c dawkowana i zastosowanie kompozycji farmaceutycznej |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: NICOX S.A. Free format text: FORMER APPLICANT(S): ASTRAZENECA AB |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: NICOX SCIENCE IRELAND Free format text: FORMER OWNER WAS: NICOX S.A |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |